

AMENDMENTS TO THE CLAIMS

Claims 1 to 40 (Cancelled)

Claim 41 (Cancelled)

Claim 42 (Cancelled)

43. (New) A method of identifying colon cancer cells that are either resistant or sensitive to a protein tyrosine kinase inhibitor comprising the step of

- (a) determining the expression profile of an expression product from at least one informative polynucleotide in a colon cancer sample, wherein said at least one informative polynucleotide is the polynucleotide encoding bone morphogenetic protein 2 (SEQ ID NO:204);
- (b) comparing the expression level of said expression product to a standard; and
- (c) determining whether said colon cancer cells are resistant or sensitive to a protein tyrosine kinase inhibitor, wherein increased expression of said expression product in said sample relative to said standard is indicative of sensitivity to a protein tyrosine kinase inhibitor, while decreased expression of said gene expression product in said sample relative to said standard is indicative of resistance to a protein tyrosine kinase inhibitor.

44. (New) The method according to Claim 41 further comprising the steps of:

- (a) determining the expression profile from an expression product of at least one additional informative polynucleotide, wherein said at least one additional informative polynucleotide is selected from the group consisting of: the polynucleotide encoding the polypeptide of SEQ ID NO:202; the polynucleotide encoding the ring finger protein 1; the polynucleotide encoding the polypeptide of SEQ ID NO:205; the polynucleotide encoding the polypeptide of SEQ ID NO:206; the polynucleotide encoding the polypeptide of SEQ ID NO:230; the polynucleotide encoding the polypeptide of SEQ ID NO:236; the polynucleotide encoding the polypeptide of SEQ ID NO:241; the

polynucleotide encoding the polypeptide of SEQ ID NO:247; and the polynucleotide encoding the polypeptide of SEQ ID NO:248;

- (b) comparing the expression level of said expression product of at least one additional informative polynucleotide to a standard;
- (c) determining whether said colon cancer cells are resistant or sensitive to a protein tyrosine kinase inhibitor, wherein increased expression of said of expression product of at least one additional informative polynucleotide in said sample relative to said standard is indicative of sensitivity to a protein tyrosine kinase inhibitor, while decreased expression of said gene expression product of at least one additional informative polynucleotide in said sample relative to said standard is indicative of resistance to a protein tyrosine kinase inhibitor.

STATUS OF THE CLAIMS

Claims 1 to 42 are cancelled.

New Claims 43 and 44 were added.

Claims 43 and 44 are pending.

Support for the new claims may be found in the specification as originally filed, and in the claims as originally presented. Specifically, support for new Claims 43 and 44 may be found in Claims 41 and 42 as previously presented, and in Examples 1 and 2, in their entirety.